5-Aminosalicylic acid (5-ASA) has been demonstrated to inhibit NF-κB activity and scavenge reactive oxygen species, making it a first-line treatment for inflammatory bowel disease (IBD). This evidence concerns the gene NFKB1 and inflammatory bowel disease.